- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-APG16L-pS287 Antibody Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP3366a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-APG16L-pS287 Antibody Blocking Peptide - Product info | |
| Primary Accession | Q676U5 |
| Clone Names | 70226183 |
| Calculated MW | 68265 Da |
Phospho-APG16L-pS287 Antibody Blocking Peptide - Additional info | |
| Gene ID 55054 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP3366a was selected from the region of human Phospho-APG16L-pS287. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Phospho-APG16L-pS287 Antibody Blocking Peptide - Protein Information | |
| Name ATG16L1 | |
| Synonyms APG16L | |
| Function Plays an essential role in autophagy: interacts with ATG12-ATG5 to mediate the conjugation of phosphatidylethanolamine (PE) to LC3 (MAP1LC3A, MAP1LC3B or MAP1LC3C), to produce a membrane-bound activated form of LC3 named LC3-II | |
| Cellular Location Cytoplasm (By similarity). Preautophagosomal structure membrane; Peripheral membrane protein (By similarity) Note=Localized to preautophagosomal structure (PAS) where it is involved in the membrane targeting of ATG5 (By similarity) | |
Phospho-APG16L-pS287 Antibody Blocking Peptide - Related products
AM1817a: ATG16L1 Antibody (Ascites)
AP1817a: ATG16L Antibody (N-term)
AP1817c: ATG16L Antibody (C-term)
AP3366a: Phospho-ATG16L-S287 Antibody
AP3442a: Phospho-ATG16L-S213 Antibody
RI10452: ATG16L1 predesign siRNA
BP1817b: APG16L Antibody (L176) Blocking Peptide
BP1817c: APG16L Antibody (C-term) Blocking Peptide
BP1817d: APG16 Antibody Blocking Peptide
Phospho-APG16L-pS287 Antibody Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). The APG12-APG5-APG16L complex is esential for the elongation of autophagic isolation membranes. This complex initially associates in uniform distribution with small vesicle membranes. During membrane elongation, the complex partitions, with a great concentration building on the outer side of the isolation membrane. Upon completion of the formation of the autophagosome, the APG12-APG5-APG16L dissociates from the membrane.
REFERENCES
Zheng H., DNA Seq. 15:303-305(2004).Clark H.F., Genome Res. 13:2265-2270(2003).Ota T., Nat. Genet. 36:40-45(2004).
